JPWO2021121444A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021121444A5 JPWO2021121444A5 JP2022536924A JP2022536924A JPWO2021121444A5 JP WO2021121444 A5 JPWO2021121444 A5 JP WO2021121444A5 JP 2022536924 A JP2022536924 A JP 2022536924A JP 2022536924 A JP2022536924 A JP 2022536924A JP WO2021121444 A5 JPWO2021121444 A5 JP WO2021121444A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- formulation according
- range
- concentration
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000012928 buffer substance Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 229950010203 nimotuzumab Drugs 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 229930195722 L-methionine Natural products 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2019000104A CU20190104A7 (es) | 2019-12-17 | 2019-12-17 | Formulación estable del anticuerpo nimotuzumab |
| CUCU-2019-0104 | 2019-12-17 | ||
| PCT/CU2020/050007 WO2021121444A2 (es) | 2019-12-17 | 2020-12-10 | Formulación estable y de alta concentración del anticuerpo nimotuzumab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023509354A JP2023509354A (ja) | 2023-03-08 |
| JPWO2021121444A5 true JPWO2021121444A5 (pt) | 2023-12-12 |
Family
ID=76478863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022536924A Pending JP2023509354A (ja) | 2019-12-17 | 2020-12-10 | 抗体ニモツズマブの安定で高濃度の製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230018364A1 (pt) |
| EP (1) | EP4079294A2 (pt) |
| JP (1) | JP2023509354A (pt) |
| KR (1) | KR20220119091A (pt) |
| CN (1) | CN114867468A (pt) |
| AU (1) | AU2020409887A1 (pt) |
| BR (1) | BR112022010488A2 (pt) |
| CA (1) | CA3163630A1 (pt) |
| CO (1) | CO2022009693A2 (pt) |
| CU (1) | CU20190104A7 (pt) |
| MX (1) | MX2022007509A (pt) |
| WO (1) | WO2021121444A2 (pt) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2654794A1 (en) * | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Lyophilized formulations of anti-egfr antibodies |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| AU2010338305A1 (en) | 2009-12-29 | 2012-05-24 | F. Hoffmann-La Roche Ag | Antibody formulation |
| US20190374639A1 (en) * | 2016-11-21 | 2019-12-12 | Polpharma Biologics S.A. | Aqueous pharmaceutical formulations |
| CN107898756B (zh) | 2017-12-22 | 2020-11-20 | 东曜药业有限公司 | 一种用于皮下或肌肉注射的高浓度尼妥珠单抗制剂及其制备方法和应用 |
-
2019
- 2019-12-17 CU CU2019000104A patent/CU20190104A7/es unknown
-
2020
- 2020-12-10 KR KR1020227024674A patent/KR20220119091A/ko active Search and Examination
- 2020-12-10 EP EP20903282.0A patent/EP4079294A2/en active Pending
- 2020-12-10 CA CA3163630A patent/CA3163630A1/en active Pending
- 2020-12-10 AU AU2020409887A patent/AU2020409887A1/en active Pending
- 2020-12-10 BR BR112022010488A patent/BR112022010488A2/pt unknown
- 2020-12-10 JP JP2022536924A patent/JP2023509354A/ja active Pending
- 2020-12-10 CN CN202080088100.8A patent/CN114867468A/zh active Pending
- 2020-12-10 US US17/786,094 patent/US20230018364A1/en active Pending
- 2020-12-10 WO PCT/CU2020/050007 patent/WO2021121444A2/es unknown
- 2020-12-10 MX MX2022007509A patent/MX2022007509A/es unknown
-
2022
- 2022-07-11 CO CONC2022/0009693A patent/CO2022009693A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| RU2339402C2 (ru) | Лиофилизированный препарат, содержащий антитела против рецептора egf | |
| WO2011012637A4 (en) | Subcutaneous anti-her2 antibody formulation | |
| JP2013500947A5 (pt) | ||
| RU2007119724A (ru) | Композиции, содержащие эктинэсайдин и дисахарид | |
| EP3681483B1 (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| RU2010142309A (ru) | Способы лечения псориаза | |
| WO2017055966A1 (en) | Low viscosity antibody compositions | |
| EP3125928A1 (en) | Liquid pharmaceutical composition of adalimumab | |
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| JP2022105056A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| JP2020515648A (ja) | リポソーム組成物及びそれを含む固体経口剤形 | |
| JPWO2021121444A5 (pt) | ||
| US20230414760A1 (en) | Pharmaceutical formulation | |
| US20210393777A1 (en) | Stable preparation comprising anti-pcsk9 antibody | |
| Fayed et al. | Optimization of amino acid-stabilized erythropoietin parenteral formula: In vitro and in vivo assessment | |
| CN113082203B (zh) | 一种免疫抑制剂单克隆抗体的液体制剂 | |
| JP2023533797A (ja) | 脂質複合体を含む経口医薬組成物 | |
| JP2009520793A (ja) | 組成物 | |
| RU2020113092A (ru) | Препараты антител против her2 для подкожного введения | |
| WO2022151940A1 (zh) | 一种稳定的帕妥珠单抗的药物组合物 | |
| JP6179939B2 (ja) | 高濃度γグロブリン製剤の粘度低下方法 | |
| WO2023140807A1 (en) | Pharmaceutical compositions of trastuzumab | |
| EA043419B1 (ru) | Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка | |
| JPWO2021087050A5 (pt) |